Talon B, Perez A, Yan C, Alobaidi A, Zhang KH, Schultz BG, Suda KJ, Touchette DR. Economic evaluations of clinical pharmacy services in the United States: 2011-2017. J Am Coll Clin Pharm. 2020 Jun;3(4):793-806. doi: 10.1002/jac5.1199
Willis SK, Mathew HM, Wise LA, Hatch EE, Wesselink AK, Rothman KJ, Mahalingaiah S. Menstrual patterns and self-reported hirsutism as assessed via the modified Ferriman-Gallwey scale: a cross-sectional study. Eur J Obstet Gynecol Reprod Biol. 2020 May 1;248:137-43. doi: 10.1016/j.ejogrb.2020.03.012
Raghunathan K, Layton JB, Ohnuma T, Shaw AD. Observational research using propensity scores. Adv Chronic Kidney Dis. 2016 Nov;23(6):367-72. doi: 10.1053/j.ackd.2016.11.010
Rodríguez-Mías NL, Martínez-Franco E, Aguado J, Sánchez E, Amat-Tardiu L. Pelvic organ prolapse and stress urinary incontinence, do they share the same risk factors? Eur J Obstet Gynecol Reprod Biol. 2015 Jul;190:52-7. doi: 10.1016/j.ejogrb.2015.04.015
Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.
Williams RE, Kalilani L, DiBenedetti DB, Zhou X, Granger AL, Fehnel SE, Levine KB, Jordan J, Clark RV. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric. 2008 Jan 1;11(1):32-43.